An investigation for investors in NASDAQ:CPRX shares was announced over potential breaches of fiduciary duties by certain Catalyst Pharmaceutical Partners directors.
Investors who purchased shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Catalyst Pharmaceutical Partners directors breached their fiduciary duties and caused damage to the company and its shareholders.
On February 17, 2016, Catalyst Pharmaceutical Partners, Inc disclosed that it has received a “Refusal To File” letter from the U.S. Food and Drug Administration (FDA) in relation to Firdapse (amifampridine phosphate), its New Drug Application. The “Refusal to File” letter explains that following December 2015 submission and the initial review, the FDA has found that the application was not adequately complete and needs additional supporting information. The letter does not note the acceptability of the clinical data and does not discuss the efficacy or safety of Firdapse. Shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) declined to as low as $0.93 per share on February 17, 2016.
On February 26, 2016, NASDAQ:CPRX shares closed at $1.05 per share.
Those who purchased NASDAQ:CPRX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego